Published in Cancer Res on May 18, 2016
Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget (2016) 0.75
Towards a better cancer precision medicine: systems biology meets immunotherapy. Curr Opin Syst Biol (2017) 0.75
Molecular classifications of gastric cancers: Novel insights and possible future applications. World J Gastrointest Oncol (2017) 0.75
Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
A new initiative on precision medicine. N Engl J Med (2015) 16.03
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Cancer immunotherapy comes of age. Nature (2011) 12.35
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) (2003) 2.48
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol (2015) 1.66
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res (2015) 1.20